Boehringer invests $65 million in early R&D centre
pharmafile | November 16, 2011 | News story | Research and Development, Sales and Marketing | Boehringer Ingelheim
Boehringer Ingelheim is investing $65 million for an early-stage research and development centre in the US.
The new 72,000 sq.ft. R&D site will be based at the company’s US headquarters in Ridgefield, Connecticut. When complete the $65 million facility will handle early stage R&D products.
If approved the products developed at the new site will move on to Boehringer Ingelheim’s full-scale R&D facilities in Ohio and Virginia, as well as Germany and Italy.
Boehringer has now invested $350 million into its US expansion projects in order to further bolster its drug discovery, development and manufacturing capabilities.
In August the company invested $42 million in a new drug safety assessment building in Connecticut. The project is scheduled to be completed in 2013 and will provide space for non-clinical safety studies.
The company also announced an $89 million expansion of its biological manufacturing facility in St. Joseph’s in Missouri.
In September, Boehringer Ingelheim Roxane opened a new $50 million high containment operations facility in Columbus, Ohio in order to meet a growing market demand for high potency and oncology products.
In addition to these capital investments, Boehringer Ingelheim gained a presence on the West Coast with the acquisition in March of Boehringer Ingelheim Fremont.
The facility, acquired from Amgen, manufactures biological medicines, and consists of more than 300,000 sq. ft. for laboratories, manufacturing and process development suitable for clinical and market supplies.
J. Martin Carroll, president and chief executive of Boehringer Ingelheim’s US operations, said: “These are exciting projects; ones that increase Boehringer Ingelheim’s research and development capabilities and reinforce our commitment to growth and innovation in the US.”
Ben Adams
Related Content
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …
Boehringer Ingelheim acquires Nerio Therapeutics, strengthening immune-oncology profile
Biopharmaceutical company Boehringer Ingelheim has announced the acquisition of drug discovery and development company Nerio …
Brainomix and Boehringer Ingelheim enter strategic partnership
Brainomix has announced that it has entered into a strategic partnership with Boehringer Ingelheim for …
